Company news
Intensity Therapeutics, Inc. news in 2024
Intensity Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast C...
December 11, 2024
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
November 20, 2024
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (...
November 17, 2024
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
November 7, 2024
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
October 30, 2024
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 7, 2024
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
July 8, 2024
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
May 14, 2024
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
May 9, 2024
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
April 1, 2024
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
March 13, 2024
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
March 13, 2024
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
February 20, 2024
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
January 2, 2024
Decks in 2024
- CTOS Annual Meeting 2024
Conference · 11 slides · 2024